Children and AIDS Community Feed

September AIDSFree Prevention Update

3 months ago
Colleagues,

The AIDSFree Prevention Update provides a sample of summaries and abstracts
of recent articles on global HIV prevention issues from a variety of
scientific, peer-reviewed journals. It also includes state-of-the-art
program resources, such as tools, curricula, program reports, and
unpublished research findings. Read it here: http://bit.ly/2gKpjEC

--
[image: JSILogo] Theresa Russo[image: Red Squares]Web Officer
PHONE: 703.528.7474 X7593 | WWW.JSI.COM <http://www.jsi.com/>[image: FB]
<http://www.facebook.com/jsihealth>[image: Twitter]
<http://www.twitter.com/jsihealth>

WHO Global Open Consultation

3 months ago
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

WHO Global Open Consultation for Innovative Personal Protective Equipment
URGENT- Please Respond
The African Society for Laboratory Medicine (ASLM) strongly encourages its membership
to respond to the World Health Organization's (WHO) request for consultation on
an innovative design for personal protective equipment (PPE). A WHO report on health
worker infections during the 2014-2016 Ebola virus epidemic in Guinea, Liberia,
and Sierra Leone found a number of deficiencies, including "inappropriate use or
lack of PPE". Factors contributing to these deficiencies ranged from challenges
in training to human factors and characteristics of PPE equipment. Technical Advisory
Committees have proposed ten "ideal characteristics" for improved PPE, which are
open for public consultation. WHO is seeking comments from institutions and organizations
as well as from individuals.
Please follow the link below for complete information and to submit comments.
Comments must be submitted by 28 September 2017.
http://www.who.int/medical_devices/document4open-consultation/en/ [http://r20.rs6.net/tn.jsp?f=001TfDR9yrD09qKTS4w8I-rSoH2lCppkcMuya_X9OKdhIf1vNhPofXUr9p7XC5-Y9gxmfWwnyuYpFKS70kOVIDo1WPfSdZo8JKYSNNE0EskVEwTqNc-rFJm5UhlsBB-g5tfau5dsgU9VHS4VOTsv9gErLodAKrmmp-48PHBGsyWC0Jh4nClBoPrJRHfuEc666GgBs0GbsQxA3ekgqrYZP8WhS_hA6pJUYpbnjiZ3Ac9jU8=&c=pMq33vQn6-KIM9JUr9VLppMJRq1VdUcDdm8c5bxVNisxu9lQFlCRUQ==&ch=5tqIjjaIoqfsCEopnPSHnmxJblb7BEd-BTDfm_nlhTc2rRMxJGBZdg==]
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

STAY CONNECTED:

Like us on Facebook [http://r20.rs6.net/tn.jsp?f=001TfDR9yrD09qKTS4w8I-rSoH2lCppkcMuya_X9OKdhIf1vNhPofXUrzOh-Fo7N4kjJDS7TPHYXtIRq3Cgyeb71uSIU7oMYLYQ5yGg5KjOw8xaZCoMSC7YCayjH6YBTWObzIYBKNelZlET8XwZlxSJFr2S8SNRVNr1PQ9a_9nQSp2J588UjvGOwlg_er1ioLC_&c=pMq33vQn6-KIM9JUr9VLppMJRq1VdUcDdm8c5bxVNisxu9lQFlCRUQ==&ch=5tqIjjaIoqfsCEopnPSHnmxJblb7BEd-BTDfm_nlhTc2rRMxJGBZdg==]

Follow us on Twitter [http://r20.rs6.net/tn.jsp?f=001TfDR9yrD09qKTS4w8I-rSoH2lCppkcMuya_X9OKdhIf1vNhPofXUr-hJ4-3BaJQXyXWX3Dh143RR_sJ1xAH0gFTXTDc3j1vAFOyY05b3RcDTc_ZlYkgOIApwf2WJ_i97vl6ZC1uPn8iy2NdERzuA4FeqUpOjrjgmGYE92dpPTLnPWGUegViJIA==&c=pMq33vQn6-KIM9JUr9VLppMJRq1VdUcDdm8c5bxVNisxu9lQFlCRUQ==&ch=5tqIjjaIoqfsCEopnPSHnmxJblb7BEd-BTDfm_nlhTc2rRMxJGBZdg==]

View our profile on LinkedIn [http://r20.rs6.net/tn.jsp?f=001TfDR9yrD09qKTS4w8I-rSoH2lCppkcMuya_X9OKdhIf1vNhPofXUr38TyE7vx4CwKDwssMEFCoPvL_7_QR2vkxvYM6yP3BmICqORxRTSELT7J8xxMy0PXp1ptjaaqYN-fpPSJD-6G4rjDy0XI6I6TWqbgRM5Me1JnkTBLSvzLg7jKPxlbt8ckYXPOSqLgoLvVBxUAGJmNRF2rXNpacDlaH26Bw5a5F0P5BTxNBUsFILMGAc7Eq9OBQ==&c=pMq33vQn6-KIM9JUr9VLppMJRq1VdUcDdm8c5bxVNisxu9lQFlCRUQ==&ch=5tqIjjaIoqfsCEopnPSHnmxJblb7BEd-BTDfm_nlhTc2rRMxJGBZdg==]

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Forward this email
http://ui.constantcontact.com/sa/fwtf.jsp?llr=6ia4m4gab&m=1107007865117&ea=$childrenandaids@knowledge-gateway.org$&a=1128890742658

This email was sent to childrenandaids@knowledge-gateway.org by communication@aslm.org.

Update Profile/Email Address
https://visitor.constantcontact.com/do?p=oo&m=001PdmkbXcRzoLSBAgj7VkEew%3D%3D&ch=e20ea1b0-8643-11e7-a875-d4ae527b6fcc&ca=6787d98b-4742-462c-a9f5-f2a83a5b95db


Instant removal with SafeUnsubscribe(TM)
https://visitor.constantcontact.com/do?p=un&m=001PdmkbXcRzoLSBAgj7VkEew%3D%3D&ch=e20ea1b0-8643-11e7-a875-d4ae527b6fcc&ca=6787d98b-4742-462c-a9f5-f2a83a5b95db


Privacy Policy:
http://www.constantcontact.com/legal/service-provider?cc=about-service-provider

Online Marketing by
Constant Contact(R)
www.constantcontact.com



ASLM | www.ASLM.org | www.ASLM2016.org | www.AJLMonline.org | Addis Ababa | Ethiopia

Webinar Wrap-Up - Tuberculosis along the lifecycle: opportunities for integration of TB/HIV and maternal health programmes.

3 months ago
MERCI INFINIMENT POUR TOUTES CES INFORMATIONS

2017-10-12 21:56 GMT+00:00 Children and AIDS <jerodrigues@unicef.org>:

>
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/e02d8cd9-f675-4eb8-b70a-d1b786512ff8.png]
>
>
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/a3478662-0c18-4b23-a736-d051ddd9a426.jpg]
>
> © UNICEF/UNI193023/Bindra
>
>
>
>
> UNICEF Learning Collaborative
> Webinar Wrap-Up
>
> Tuberculosis along the lifecycle: opportunities for integration of TB, HIV
> and
> maternal health programmes
>
>
>
>
>
> On *Thursday, October 5th, 2017 *UNICEF and CDC in collaboration with the
> Child Survival Working Group organised a webinar: *Tuberculosis along the
> lifecycle: opportunities for integration of TB/HIV and maternal health
> programmes.*
>
> The webinar was moderated by Anne Detjen, UNICEF, Surbhi Modi, CDC and
> Jessica Rodrigues, UNICEF. A total of 86 participants from more than 15
> countries (including Greenland) attended the webinar.
>
> *Webinar Recording <http://childrenandaids.org/node/428>*
>
> *Presentations:*
>
> - *TB in women, infants, children and adolescents – key data, gaps and
> opportunities* <http://childrenandaids.org/node/428>
> Steve Graham, University of Melbourne and The International Union
> Against TB and Lung Disease
> - *Addressing TB along the lifecycle – lessons from Uganda*
> <http://childrenandaids.org/node/428>
> Moorine Sekadde, National TB Programme, Uganda
> - *Kenya's experience providing Isoniazid Preventive Therapy in PMTCT
> settings <http://childrenandaids.org/node/428>*
> Immaculate Kathure, National TB Programme, Kenya
>
> *Additional Resources:*
> The 48th Union World Conference on Lung Health will be held this week from
> 11-14 October in Guadalajara, Mexico. For more information, please visit
> the *website* <https://www.theunion.org/>.
>
> *More Information:*
>
> For technical questions, please contact Anne Detjen at adetjen@unicef.org
> or Surbhi Modi at bkt1@cdc.gov
>
> If you are interested in collaborating with us on a webinar, please
> contact Jessica Rodrigues at jerodrigues@unicef.org.
>
>
>
>
>
>
>
>
>
> *Children and AIDS Site* <http://www.childrenandaids.org/>
>
>
>
>
>
>
>
> Please visit the Children and AIDS community homepage to view discussion
> archives, library, and more! http://knowledge-gateway.org/childrenandaids
>
> You are receiving this message because you are a member of the community Children
> and AIDS <https://knowledge-gateway.org/childrenandaids>.
>
> View this contribution on the web site
> <https://knowledge-gateway.org/_/md1plzb0>
>
> A reply to this message will be sent to all members of Children and AIDS.
>
> Reply to sender <jerodrigues@unicef.org> | Unsubscribe
> <leave.childrenandaids@knowledge-gateway.org>
>



--

*La grâce de Dieu me suffit*


*SEMI LOU BERTINE 4011 81 18 / 05 70 18 69*

UNICEF Learning Collaborative Webinar: PATA Regional Summit 23rd-25th October 2017

3 months ago
Thanks,Jessica, please note that we are together!But we are working hard under the CIPHER Project too!


Maurice MUDIMBE KALUNGU Directeur Exécutif National de la COPDECO-ONGD Tél.:+243-998123505; +243-817660960

Le mardi 17 octobre 2017 à 23:26:26 UTC+2, Children and AIDS <jerodrigues@unicef.org> a écrit :


 

|
|
|
|

|

|


 

|
|

|
|
© UNICEF/UN063426/Schermbrucker – Malawi
|

|


 

|
|
                             
|

|


 

|
|
UNICEF Learning Collaborative

UNICEF
and
Pediatric Adolescent Treatment Africa (PATA) 
join forces to bring to you a real time webinar series 

from the PATA 2017 Continental Summit
Towards an AIDS free Africa - Delivering on the Frontline
23 - 25 October 2017 
|

|


 

| |


 

|
|
On October 23rd, 24th and 25th 2017, UNICEF and PATA will lead a webinar series to share select presentations from the PATA Regional Summit in Johannesburg. These presentations will include plenary presentations and country-led solutions to identifying, treating and caring for children and adolescents living with HIV and affected by HIV. 

The links to the webinar are below:
October 23rd  9-10am EST and 3-4pm JHB
October 24th  9-10am EST and 3-4pm JHB    
October 25th  8.30-9.30am EST and 2.30-3.30pm JHB  

Join us next week to hear from the frontline workers and health care providers who work tirelessly to deliver comprehensive care to children and adolescents.  Stay tuned for more details as we get closer to the PATA Regional Summit. 

For more information on the PATA Regional Summit, please visit the PATA website. 
For questions, please contact Jessica Rodrigues at jerodrigues@unicef.org
|

|


 

|
| |

|


 

|
|

|


|

|

|


 

|
| |

|



|
|
| |


 

| |



|
|
|
|
Children and AIDS Site
|

|


 

| |


 

|
|
| |

|

|



|

|


 

 

Please visit the Children and AIDS community homepage to view discussion archives, library, and more! http://knowledge-gateway.org/childrenandaids

You are receiving this message because you are a member of the community Children and AIDS.

View this contribution on the web site

A reply to this message will be sent to all members of Children and AIDS.

Reply to sender | Unsubscribe

 

.........................................................................................................................................

àJoin Skype Meeting     

Trouble Joining? Try Skype Web App

Join by phone

 

United States : +16467571480 (Global)                        English (United States)

Switzerland : +41225083200 (Global)                           English (United States)  

Hungary : +3617909400 (Global)                    English (United States)  

United Kingdom : +443300102423 (Global)                 English (United Kingdom)  

Jordan : +96265509679 (Global)                     Arabic (Saudi Arabia)  

Panama : +5073017399 (Global)                    English (United States)  

Cambodia : +85523260206 (Global)                              English (United Kingdom)  

South Africa : +27879403508 (Global)                          English (United Kingdom)  

Bulgaria : +35924928220 (Global)                  English (United Kingdom)  

Denmark : +4578793993 (Global)                   English (United States)  

France : +33176542732 (Global)                     French (France)  

Netherlands : +31705680050 (Global)                          English (United States)  

Australia : +61730628687 (Global)                 English (Australia)  

Brazil : +556136860910 (Global)                     Portuguese (Brazil)  

Belgium : +3228087101 (Global)                    French (France)  

Greece : +302112340299 (Global)                  English (United Kingdom)  

Italy : +390697632494 (Global)                       Italian (Italy)  

Albania : +35544548424 (Global)                   English (United Kingdom)  

 

Find a local number

 

Conference ID: 82986684

Forgot your dial-in PIN?|Help  

 

[!OC([1033])!]

.........................................................................................................................................

 

 

.........................................................................................................................................

àJoin Skype Meeting     

Trouble Joining? Try Skype Web App

Join by phone

 

United States : +16467571480 (Global)                        English (United States)

Switzerland : +41225083200 (Global)                           English (United States)  

Hungary : +3617909400 (Global)                    English (United States)  

United Kingdom : +443300102423 (Global)                 English (United Kingdom)  

Jordan : +96265509679 (Global)                     Arabic (Saudi Arabia)  

Panama : +5073017399 (Global)                    English (United States)  

Cambodia : +85523260206 (Global)                              English (United Kingdom)  

South Africa : +27879403508 (Global)                          English (United Kingdom)  

Bulgaria : +35924928220 (Global)                  English (United Kingdom)  

Denmark : +4578793993 (Global)                   English (United States)  

France : +33176542732 (Global)                     French (France)  

Netherlands : +31705680050 (Global)                          English (United States)  

Australia : +61730628687 (Global)                 English (Australia)  

Brazil : +556136860910 (Global)                     Portuguese (Brazil)  

Belgium : +3228087101 (Global)                    French (France)  

Greece : +302112340299 (Global)                  English (United Kingdom)  

Italy : +390697632494 (Global)                       Italian (Italy)  

Albania : +35544548424 (Global)                   English (United Kingdom)  

 

Find a local number

 

Conference ID: 82986684

Forgot your dial-in PIN?|Help  

 

[!OC([1033])!]

.........................................................................................................................................

 

 

.........................................................................................................................................

àJoin Skype Meeting     

Trouble Joining? Try Skype Web App

Join by phone

 

United States : +16467571480 (Global)                        English (United States)

Switzerland : +41225083200 (Global)                           English (United States)  

Hungary : +3617909400 (Global)                    English (United States)  

United Kingdom : +443300102423 (Global)                 English (United Kingdom)  

Jordan : +96265509679 (Global)                     Arabic (Saudi Arabia)  

Panama : +5073017399 (Global)                    English (United States)  

Cambodia : +85523260206 (Global)                              English (United Kingdom)  

South Africa : +27879403508 (Global)                          English (United Kingdom)  

Bulgaria : +35924928220 (Global)                  English (United Kingdom)  

Denmark : +4578793993 (Global)                   English (United States)  

France : +33176542732 (Global)                     French (France)  

Netherlands : +31705680050 (Global)                          English (United States)  

Australia : +61730628687 (Global)                 English (Australia)  

Brazil : +556136860910 (Global)                     Portuguese (Brazil)  

Belgium : +3228087101 (Global)                    French (France)  

Greece : +302112340299 (Global)                  English (United Kingdom)  

Italy : +390697632494 (Global)                       Italian (Italy)  

Albania : +35544548424 (Global)                   English (United Kingdom)  

 

Find a local number

 

Conference ID: 95219917

Forgot your dial-in PIN?|Help  

 

[!OC([1033])!]

.........................................................................................................................................

Collect M&E Data Using Mobile phones

3 months ago
Dear Colleagues,

Have you always wanted to learn how to collect M&E data using mobile phones?

We take this opportunity to invite you to register and attend our 5 days
training course in Mobile Data Collection and Mapping For M&E and
Scientists.

COURSE DATE REGISTRATION LINK
1. 16 to 20th July 2018
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=7dd2ef392c&e=aae1dd1afa> - Register online here
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=71290b7e08&e=aae1dd1afa>
2. 13th to 17th August 2018
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=cf2e1ab58f&e=aae1dd1afa> - Register online here
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=88818ad91f&e=aae1dd1afa>
3. 17th to 21 September 2018
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=57b08f0112&e=aae1dd1afa> - Register online here
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=048de199bf&e=aae1dd1afa>
4. 15th to 19th October 2018
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=80fdb8888d&e=aae1dd1afa> - Register online here
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=2826d10031&e=aae1dd1afa>
5. 19th to 23rd November 2018
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=095c663232&e=aae1dd1afa> - Register online here
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=f54e1cc800&e=aae1dd1afa>
6. 10th to 14th December 2018
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=677f6e74c6&e=aae1dd1afa> - Register online here
<https://t4d.us18.list-manage.com/track/click?u=01fb1c5bef5758781fc85ae7f&id
=b354f40ddf&e=aae1dd1afa>

COURSE OBJECTIVES

This course will introduce participants to tools, techniques, and
technologies for data collection using mobile phones and devices.



At the end of the course, participants will be able to:
1. Digitize/transform questionnaire into mobile compatible formats.
2. Set up a cloud server for survey data hosting.
3. Configure mobile phones/devices for data collection.
4. Collect data offline (Without internet connection).
5. Upload data to a cloud server.
6. Visualize and analyze data online.
7. Download data for analysis.
8. Develop maps from survey data.



SOFTWARE AND PLATFORMS TO BE COVERED

* ODK - Open Data Kit
* KoBoToolbox
* Magpi
* QGIS
* Microsoft Excel



CONTACT DETAILS
Email: outreach@t4d.co.ke <mailto:outreach@t4d.co.ke>
Tel: +254 706909947
Website: www.t4d.co.ke <http://www.t4d.co.ke>

Kind regards.
Jeff Karani.
Team Leader.
Tech For Development
Innovation for impact

RE: UNICEF at AIDS 2018 - Adolescents Living with HIV-RUNNING POSITIVE- A REAL LIFE STORY

3 months ago
Dear Colleagues

As you may know for many years now UNAIDS has been supporting the Adolescents Living with HIV in India to become true champions of - really living with HIV- and building a real life despite all the challenges and setbacks because of the disease and the society.

We have supported two of them who have participated in many sport events especially marathons here at home and around the globe to document their life stories from the beginning of the journey until now into a movie called RUNNING POSITIVE which will be launched in Amsterdam during the International AIDS Conference.

We do wish that this movie will bring hope in the life of the 2.1 million Adolescents living with HIV around the world and who are facing same challenges with adherence to treatment, schooling, getting a job, family life, living a normal life in the society, etc.

The launch of the movie will be on the 23rd of July 2018 from 17.00 hours to 19.00 hours at the Global Village, and you are invited to come and support our YOUNG CHAMPIONS at that world stage.

Please do not hesitate to contact me or my colleague Ms Nandini Kapoor at KapoorN@unaids.org

Best regards.

Dr Bilali CAMARA
Medical Epidemiologist
UNAIDS Country Director for India
Email: camarab@unaids.org
UNHOUSE 55 Lodi Estate, New Delhi, India 110003
www.unaids.org<http://www.unaids.org>
in.one.un.org


From: childrenandaids@knowledge-gateway.org <childrenandaids@knowledge-gateway.org> On Behalf Of Children and AIDS
Sent: 19 June 2018 00:13
To: Children and AIDS <childrenandaids@knowledge-gateway.org>
Subject: [childrenandaids] UNICEF at AIDS 2018




[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/e02d8cd9-f675-4eb8-b70a-d1b786512ff8.png]



Join UNICEF at AIDS 2018



[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/a9d701ac-1dc0-42a9-9ad3-f5fd12a796ac.jpg]



Save the Dates




[© UNICEF/UN061613/Dejongh]

Sylla Mariani, a mother living with HIV, shares a sweet moment with her two children, Côte d'Ivoire, March 2017.
© UNICEF/UN061613/Dejongh






The Last Mile to EMTCT: Are we there yet?




Monday, July 23
08:00 - 10:00h

Venue: Auditorium

Breakfast will be provided.




This session, convened by the PMTCT partners, will aim to answer three questions: (1) Where are we now and where do we need to go?; (2) What are the game changers and innovations that will get us to the finish line?; and (3) How can we better use data for quality improvement and monitoring progress?

Speakers will include representatives from governments and civil society, ICAP, OGAC, UNAIDS, UNICEF and WHO.

Event conveners: ICAP, UNAIDS, UNICEF and WHO



Register for the Last Mile<https://docs.google.com/forms/d/e/1FAIpQLSfNAvfecFPtj5iUjt4BruWYahvNIluxttH_APwJLK0bJBmLYg/viewform?usp=sf_link>



Diagnose, Treat, Innovate: A Paradigm Shift for Ending Paediatric

AIDS




Monday, July 23
12:30 - 14:30h

Venue: Hall 11B

Refreshments will be provided.




This session will highlight game-changing innovations for paediatric HIV diagnosis, treatment and monitoring as well as evidence supporting their readiness for scale-up and opportunities for these innovations to complement the role of PMTCT programmes in the elimination of paediatric AIDS.

Speakers include: Smiljka de Lussigny (Unitaid); Ndlovu Nqobile (ASLM); Trevor Peter (CHAI); Rebecca Bailey (EGPAF); Victor Musiime (DNDi); Chewe Luo (UNICEF); George Siberry (PEPFAR); Surbhi Modi (CDC).

Event Conveners: ASLM, CHAI, DNDi, EGPAF, UNICEF and Unitaid



Register for Diagnose, Treate, Innovate<https://docs.google.com/forms/d/e/1FAIpQLSeUgQdmPaPruXOtxWykpl6rPjIo3pe4m1nkVNGriJ1DEEc9Bw/viewform?usp=sf_link>



Women Leaders in the Global HIV Response for Children




Wednesday, July 25
15:30 - 17:00h

Venue: Okura Hotel, Amsterdam

Refreshments will be provided.




UNICEF launches a new report examining the global HIV response for children, adolescents and young women from the perspectives of extraordinary women leaders who have led the response in their spheres and made it their life's work. The report tells a compelling story of the remarkable successes achieved over the course of 30 years of the epidemic, the difficulties encountered and the challenges overcome, and what lies ahead on the continuing road to ending AIDS for children and for all. UNICEF Executive Director Henrietta H. Fore will host the event which is sponsored in part by the Okura Hotel.



Register for Women Leaders in Global HIV<https://docs.google.com/forms/d/e/1FAIpQLSfufwZM5xpo0CqzZjsen19pi_JqcsVWqchgMxvLxcYqiI_8wQ/viewform?usp=sf_link>



Scaling Breakthrough Innovations to Transform

Adolescent AIDS Services




Wednesday, July 25
18:30 - 20:30h

Venue: E105-108

Refreshments will be provided.




This dialogue will identify critical themes that could inform the future of the global adolescent AIDS response. Panelists will reflect on the complex innovation landscape; discuss ways to move differentiated service delivery models and technological innovations beyond pilot scale; and examine the leadership, policy and systems attributes that have enabled transformative scaling up of adolescent-responsive services in selected contexts.

Speakers include: Henrietta Fore (Executive Director, UNICEF); TD Ciarán Cannon (Irish Minister of State for the Diaspora and International Development); HE Dr. Alfred Madigele (Minister of Health Botswana); Dr. Sani Aliyu (Director-General, NACA, Nigeria); Prof. Linda-Gail Bekker (President, IAS); Catherine Sozi (Director, Regional Support Team for Eastern and Southern Africa, UNAIDS); Dr. Nduku Kilonzo (Director, NACC, Kenya).

Event Conveners: UNICEF, UNAIDS, Irish AID



Register for Scaling Breakthrough Innovations<https://docs.google.com/forms/d/e/1FAIpQLSepL1buHwuY-NUcmBKUkY3pJfE7Ka23C_w0tfB01y-cE6SC_Q/viewform?usp=sf_link>



SHE is the Future: Adolescent Girl and Young Women's Engagement

in a More Effective National Prevention Response




Thursday, July 26
07:00 - 08:30h

Venue: G104-105

Breakfast will be provided.




This dialogue will give voice to the hopes, dreams, and aspirations of the next generation of female leaders in the HIV response. Panelists will showcase innovative campaigns to galvanize a sustainable movement; stimulate intergenerational dialogue on how country-owned responses have elevated AGYW participation in the national and regional discourse; and examine whether existing investments are sufficient to turn the tide.

Speakers include Henrietta Fore (Executive Director, UNICEF), Ambassador Deborah L. Birx (U.S. Global AIDS Coordinator and Special Rep. for Global Health Diplomacy); Dr. Marijke Wijnroks (Chief of Staff, The Global Fund to Fight AIDS, TB & Malaria); HE Monica Geingos (First Lady of Namibia & UNAIDS Goodwill Ambassador, Adolescent Girls and Young Women), Prof. Linda-Gail Bekker (President, IAS); Julie Pulerwitz, (Director, HIV and AIDS, Population Council); and government leaders from Jamaica, South Africa and Zimbabwe.

Event Conveners: UNICEF, PEPFAR, IAS



Register for SHE is the Future<https://docs.google.com/forms/d/e/1FAIpQLSf0EDtJpEmt7clhCkMmYixgi9cvvAuX86-h7PtAVZLbsL--lw/viewform?usp=sf_link>



Key Considerations and Implementation Tools for Introducing

New HIV Point-of-Care Diagnostic Technologies into National Health

Programs




Thursday, July 26
18:30 - 20:30h

Venue: G104-105

Refreshments will be provided.




Many countries in Africa have introduced and are scaling up routine point-of-care (POC) early infant diagnosis (EID), and are also considering the targeted use of POC viral load (VL) testing within their national health programmes. To support countries with implementation, global health partners recently launched two complementary resources: Key Considerations for Introducing New HIV Point of Care Diagnostic Technologies in National Health Systems and the HIV Point-of-Care Diagnostics Toolkit. This session will highlight the specific contributions of these new resources, both of which are based upon robust implementation experience from more than 10 countries.

Speakers will include representatives from Ministries of Health, UNICEF, Unitaid, WHO, OGAC, ASLM, CHAI, EGPAF, and the International Coalition of Women Living with HIV (ICW).

Event Conveners: ASLM, CHAI, EGPAF, UNICEF and Unitaid



Register for New HIV PoC Diagnostic Technologies<https://docs.google.com/forms/d/e/1FAIpQLSf7LIPlKBjWaY_He80H7jnUrNUD2K3kxUiCCDAhSfEIR1zpBQ/viewform?usp=sf_link>
















[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/af3a38ff-6e01-4998-a2d4-cc8917e28b1c.png]



Children and AIDS Site<http://www.childrenandaids.org/>









Jessica Rodrigues, MS
Programme Specialist (Partnerships and Learning)
UNICEF, HIV Section
3 UN Plaza
917 265-4533

[UNICEF logo horizontal]



Please visit the Children and AIDS community homepage to view discussion archives, library, and more! http://knowledge-gateway.org/childrenandaids

You are receiving this message because you are a member of the community Children and AIDS<https://knowledge-gateway.org/childrenandaids>.

View this contribution on the web site<https://knowledge-gateway.org/_/hq4al6jb>

A reply to this message will be sent to all members of Children and AIDS.

Reply to sender<mailto:jerodrigues@unicef.org> | Unsubscribe<mailto:leave.childrenandaids@knowledge-gateway.org>

Communique from ICW ISC to ICW Members and Friends

3 months ago
ICW Members, Partners and Friends

 

We write to you in the spirit of transparency and accountability as we believe in the leadership of women living with HIV and we are champions of ICW.  We write to you to share concerns regarding the governance and management of ICW as a global network that leaves the network unable to lead and bring women living with HIV together..  Our efforts to internally ask questions and resolve concerns have not worked and we see an increase in questionable actions so we feel we have no alternative but to speak publicly.




1. We have raised concerns on conflict of interest and possible mismanagement of funds by the Global Director who has traveled with her husband to Bangkok in November on Business class paid for with ICW funds. No investigation has been done to clear doubts raised by six ICW members or to resolve any potential misunderstanding. ICW Global Director has continued to fly with her husband on multiple ICW funded work trips in 2018. We are concerned that ICW global office procured printing of the ICW Strategic Plan from a business managed by ICW Director’s husband even way before the plan was approved by the ISC and ICW regions.




2. We are concerned that the November 2017 ISC meeting was not convened as guided by ICW Constitution.  ICW Director did not ensure that all new and returning members of the ISC would be present for the board meeting held in Bangkok. Five Board members (who were subsequently dismissed from the Board, were surprised to discover that their flights would depart immediately after reviewing the ICW Strategic Plan, before board meeting and elections of board officials thus excluding voting members form African regions and North America from participating.




3. Despite concerns being raised regarding conflict of interest and possible mismanagement by 6 Board members, ICW Chairperson renewed the contract of the Global director without a formal appraisal as defined by the constitution and Governance Manual.

 

4. A public communication went from the ICW Chairperson on May 8th that mentioned changes to the International Steering Committee (ISC) of the International Community of Women Living HIV (ICW). The communication mentioned that there would be rumors from within the ICW family as a result of these changes. 

 

5. Following that announcement, six ICW board members received a letter from the ICW Chairperson – Marama Pala on May 24th 2018, that they had been removed from the board.

 

6. In the spirit of transparency and accountability, the six board members are; Adrienne Munene – ICW Eastern Africa; Monisola Elizabeth Ajiboye – ICW West Africa; Louki Banguitoumba Tatiana –Central Africa; Sharon Mashamba –Southern Africa; Martha Cameron and Brittany Cameron from ICW North America.  Prior to their dismissal, all six members had raised questions regarding the management and governance of ICW Global Network.

 

7. We sought for explanation on the above-mentioned concerns but none was coming forth.  In our duty to ICW and to women living with HIV, we were not satisfied with the silence and lack of action thus we wrote a letter of no confidence on the chairperson in a letter dated March 13th 2018. This information was also copied to ICW funders for the purpose of transparency and accountability because we had concerns with financial management.

 

8. We requested for a meeting either virtually or in person to discuss a way forward for all board members to be led by a reputable and independent arbitration committee but the response was removal of all six members mentioned above from any communication and eventually receiving notice of their removal from the board.




9. We, the six members have since then reached out to UNAIDS and UN Women for support in mediating. UNAIDS and UN Women have committed to support in bringing all ICW leaders together from different regions to discuss and agree on a way forward. We have however learned that ICW Global Director – Rebecca have rejected the support offered.



10. The Kenya NGO Board – a government Department that regulates operations of NGO’s in Kenya received allegations and complaints from some ICW members, on the unconstitutional removal of six members from ICW Board, abuses of power, and possible irregularities. The Kenya NGO Board gave a notice to ICW Director on their intent to do a forensic audit of the organization on June 12th 2018..  ICW Trustee members have reported that Rebecca has refused to comply and since then ICW office has not been occupied.
As leaders from different regions within the ICW family, our aim has been to seek for clarity on the questions and concerns mentioned above in accordance with our mandate as a governing body. As we hold our leaders, and others accountable, we want to set the same standard for ourselves. Our reputation is at stake and the credibility of the only global network by and for women living with HIV..

We are committed to ensure that ICW ‘weather this storm and have already put strategies in place to remain united and move ICW forward. We value the role of membership in this network. ICW has always been a strong Network, one where decisions have been made on a collaborative basis, with the best interest of our members, who are women living with HIV

 

We will remain committed to ensuring that the network remains to its core of holding others to account by doing the same internally. We are committed to ensure that women living with HIV are not only at the centre of the HIV response but also take leadership in the wider global health agenda.

 

Approved by: ISC Board Members

 

Martha N Cameron; Adrienne Munene; Monisola Elizabeth Ajiboye; Louki Banguitoumba Tatiana; Sharon Mashamba; Brittany Cameron.

Attachments
Press Release - ICW - ISC Statement.pdf

AIDSFree Annual Report

3 months ago
This annual report presents AIDSFree's programmatic achievements at both
central and country levels for October 1, 2016 to September 30, 2017.The
Strengthening High Impact Interventions for an AIDS-free Generation
(AIDSFree) Project in 2016–17 worked to set the stage for the next step in
the control of the HIV epidemic. In this, its third project year, AIDSFree
fulfilled its mission to expand HIV education, prevention, and treatment in
14 countries and the Middle East/North Africa region, while simultaneously
working to support the infrastructure that will lead to long-term
sustainable containment of the epidemic. Read the report here:
http://bit.ly/2wHC0vh

--
[image: JSILogo] Theresa Russo[image: Red Squares]Web MANAGER
PHONE: 703.528.7474 X7593 | WWW.JSI.COM <http://www.jsi.com/>[image: FB]
<http://www.facebook.com/jsihealth>[image: Twitter]
<http://www.twitter.com/jsihealth>

10th Annual International Workshop on HIV Paediatrics at AIDS 2018

3 months ago
Thank you for the information


On Tue, Jun 19, 2018 at 6:05 PM Children and AIDS <jerodrigues@unicef.org>
wrote:

>
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/e02d8cd9-f675-4eb8-b70a-d1b786512ff8.png]
>
>
>
>
>
> UNICEF Learning Collaborative
> is pleased to share an invite for the
>
>
>
>
> International Workshop on HIV Pediatrics
>
>
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/d082c985-beb5-4afe-bb28-771b9d89156d.png]
> <http://www.virology-education.com/event/upcoming/10th-workshop-hiv-pediatrics/>
>
> Virology Education invites you to attend the *10th **Annual International
> Workshop on HIV Pediatrics 2018 *on 20 and 21 July 2018 in Amsterdam, the
> Netherlands.
>
> The International Workshop on HIV Pediatrics focuses on research in
> prevention and treatment of HIV infections in infants, children and
> adolescents. The annual workshop has been held alongside the International
> AIDS Conference since 2009 and brings together global experts in
> paediatric, adolescent and maternal HIV research.
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/101ef220-a997-4339-a060-11ff01ff668b.jpg]
> <http://www.virology-education.com/event/upcoming/10th-workshop-hiv-pediatrics/>
>
> *Learn more about the workshop and register *
> <http://www.virology-education.com/event/upcoming/10th-workshop-hiv-pediatrics/>
> *here*
> <https://virology.eventsair.com/10ped18/10pedregistration/Site/Register>
> *. *
> <http://www.virology-education.com/event/upcoming/10th-workshop-hiv-pediatrics/>
>
>
>
>
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/4752c44e-7697-48ef-ba69-6f11f890566c.png]
>
>
>
> *Children and AIDS Site* <http://www.childrenandaids.org/>
>
>
>
> Please visit the Children and AIDS community homepage to view discussion
> archives, library, and more! http://knowledge-gateway.org/childrenandaids
>
> You are receiving this message because you are a member of the community Children
> and AIDS <https://knowledge-gateway.org/childrenandaids>.
>
> View this contribution on the web site
> <https://knowledge-gateway.org/_/q0zdk4r4>
>
> A reply to this message will be sent to all members of Children and AIDS.
>
> Reply to sender <jerodrigues@unicef.org> | Unsubscribe
> <leave.childrenandaids@knowledge-gateway.org>
>

UNICEF at AIDS 2018

3 months ago
Thanks!

Maurice MUDIMBE KALUNGU Directeur Exécutif National de la COPDECO-ONGD Tél.:+243-998123505; +243-817660960

Le lundi 25 juin 2018 à 17:01:57 UTC+2, Children and AIDS <jerodrigues@unicef.org> a écrit :


 

 

|
| |
| |
|
|
|

|

|


 

|
|
Join UNICEF at AIDS 2018
|

|


 

|
|

|

|


 

|
|
|
Save the Dates
|

|

|


 

|
|

|
|
Sylla Mariani, a mother living with HIV, shares a sweet moment with her two children, Côte d'Ivoire, March 2017.
© UNICEF/UN061613/Dejongh
|

|


 

|
| |

|


 

|
|
|
The Last Mile to EMTCT:  Are we there yet?
|

|

|


 

|
|
|
Monday, July 23  
08:00 – 10:00h 

Venue: Auditorium

Breakfast will be provided.
|

|

|


 

|
|
This session, convened by the PMTCT partners, will aim to answer three questions: (1) Where are we now and where do we need to go?; (2) What are the game changers and innovations that will get us to the finish line?; and (3) How can we better use data for quality improvement and monitoring progress? 

Speakers will include representatives from governments and civil society, ICAP, OGAC, UNAIDS, UNICEF and WHO.

Event conveners: ICAP, UNAIDS, UNICEF and WHO
|

|


 

|
|
Register for the Last Mile
|

|


 

|
|
|
Diagnose, Treat, Innovate: A Paradigm Shift for Ending Paediatric

AIDS
|

|

|


 

|
|
|
Monday, July 23

12:30 – 14:30h 


Venue: Hall 11B
 

Refreshments will be provided.
|

|

|


 

|
|
This session will highlight game-changing innovations for paediatric HIV diagnosis, treatment and monitoring as well as evidence supporting their readiness for scale-up and opportunities for these innovations to complement the role of PMTCT programmes in the elimination of paediatric AIDS.

Speakers include: Smiljka de Lussigny (Unitaid); Ndlovu Nqobile (ASLM); Trevor Peter (CHAI); Rebecca Bailey (EGPAF); Victor Musiime (DNDi); Chewe Luo (UNICEF); George Siberry (PEPFAR); Surbhi Modi(CDC).

Event Conveners:  ASLM, CHAI, DNDi, EGPAF, UNICEF and Unitaid
|

|


 

|
|
Register for Diagnose, Treate, Innovate
|

|


 

|
|
|
Women Leaders in the Global HIV Response for Children
|

|

|


 

|
|
|
Wednesday, July 25

15:30 – 17:00h 


Venue: Okura Hotel, Amsterdam
 

Refreshments will be provided.
|

|

|


 

|
|
UNICEF launches a new report examining the global HIV response for children, adolescents and young women from the perspectives of extraordinary women leaders who have led the response in their spheres and made it their life’s work. The report tells a compelling story of the remarkable successes achieved over the course of 30 years of the epidemic, the difficulties encountered and the challenges overcome, and what lies ahead on the continuing road to ending AIDS for children and for all. UNICEF Executive Director Henrietta H. Fore will host the event which is sponsored in part by the Okura Hotel. 
|

|


 

|
|
Register for Women Leaders in Global HIV
|

|


 

|
|
|
Scaling Breakthrough Innovations to Transform

Adolescent AIDS Services 
|

|

|


 

|
|
|
Wednesday, July 25

18:30 – 20:30h 


Venue: E105-108
 

Refreshments will be provided.
|

|

|


 

|
|
This dialogue will identify critical themes that could inform the future of the global adolescent AIDS response. Panelists will reflect on the complex innovation landscape; discuss ways to move differentiated service delivery models and technological innovations beyond pilot scale; and examine the leadership, policy and systems attributes that have enabled transformative scaling up of adolescent-responsive services in selected contexts.

Speakers include: Henrietta Fore (Executive Director, UNICEF); TD Ciarán Cannon (Irish Minister of State for the Diaspora and International Development); HE Dr. Alfred Madigele (Minister of Health Botswana); Dr. Sani Aliyu (Director-General, NACA, Nigeria); Prof. Linda-Gail Bekker (President, IAS); Catherine Sozi (Director, Regional Support Team for Eastern and Southern Africa, UNAIDS); Dr. Nduku Kilonzo (Director, NACC, Kenya).

Event Conveners:  UNICEF, UNAIDS, Irish AID
|

|


 

|
|
Register for Scaling Breakthrough Innovations
|

|


 

|
|
|
SHE is the Future: Adolescent Girl and Young Women’s Engagement

in a More Effective National Prevention Response
|

|

|


 

|
|
|
Thursday, July 26

07:00 – 08:30h 


Venue: G104-105
 

Breakfast will be provided.
|

|

|


 

|
|
This dialogue will give voice to the hopes, dreams, and aspirations of the next generation of female leaders in the HIV response. Panelists will showcase innovative campaigns to galvanize a sustainable movement; stimulate intergenerational dialogue on how country-owned responses have elevated AGYW participation in the national and regional discourse; and examine whether existing investments are sufficient to turn the tide.

Speakers include Henrietta Fore (Executive Director, UNICEF), Ambassador Deborah L. Birx (U.S. Global AIDS Coordinator and Special Rep. for Global Health Diplomacy); Dr. Marijke Wijnroks (Chief of Staff, The Global Fund to Fight AIDS, TB & Malaria); HE Monica Geingos (First Lady of Namibia & UNAIDS Goodwill Ambassador, Adolescent Girls and Young Women), Prof. Linda-Gail Bekker (President, IAS); Julie Pulerwitz, (Director, HIV and AIDS, Population Council); and government leaders from Jamaica, South Africa and Zimbabwe.

Event Conveners:  UNICEF, PEPFAR, IAS
|

|


 

|
|
Register for SHE is the Future
|

|


 

|
|
|
Key Considerations and Implementation Tools for Introducing

New HIV Point-of-Care Diagnostic Technologies into National Health

Programs
|

|

|


 

|
|
|
Thursday, July 26

18:30 – 20:30h 


Venue: G104-105
 

Refreshments will be provided.
|

|

|


 

|
|
Many countries in Africa have introduced and are scaling up routine point-of-care (POC) early infant diagnosis (EID), and are also considering the targeted use of POC viral load (VL) testing within their national health programmes. To support countries with implementation, global health partners recently launched two complementary resources: Key Considerations for Introducing New HIV Point of Care Diagnostic Technologies in National Health Systems and the HIV Point-of-Care Diagnostics Toolkit. This session will highlight the specific contributions of these new resources, both of which are based upon robust implementation experience from more than 10 countries.

Speakers will include representatives from Ministries of Health, UNICEF, Unitaid, WHO, OGAC, ASLM, CHAI, EGPAF, and the International Coalition of Women Living with HIV (ICW).

Event Conveners:  ASLM, CHAI, EGPAF, UNICEF and Unitaid
|

|


 

|
|
Register for New HIV PoC Diagnostic Technologies
|

|


 

|
| |

|


 

|
| |

|



|
|
| |


 

| |



|
|
|
| |

|


 

|
|

|

|


 

|
|
Children and AIDS Site
|

|


 

|
| |

|



|

|


 

 

Jessica Rodrigues, MS

Programme Specialist (Partnerships and Learning)

UNICEF, HIV Section

3 UN Plaza

917 265-4533

 



 

 

Please visit the Children and AIDS community homepage to view discussion archives, library, and more! http://knowledge-gateway.org/childrenandaids

You are receiving this message because you are a member of the community Children and AIDS.

View this contribution on the web site

A reply to this message will be sent to all members of Children and AIDS.

Reply to sender | Unsubscribe

Join us July 11th for a Webinar on Addressing adolescent girl and young women's risk and empowerment: Emerging lessons from the DREAMS Partnership

3 months ago
Thanks!

Maurice MUDIMBE KALUNGU Directeur Exécutif National de la COPDECO-ONGD Tél.:+243-998123505; +243-817660960

Le mardi 3 juillet 2018 à 19:19:35 UTC+2, Children and AIDS <jerodrigues@unicef.org> a écrit :


 

 

|
|
 

|
|

|

|


 

|
|
UNICEF Learning Collaborative

is pleased to invite you to a

Webinar with Population Council


Hosted by UNICEF HIV and Gender Sections
 
|

|


 

|
|
|
Addressing adolescent girl and young women's risk and empowerment: 
Emerging lessons from the DREAMS Partnership
|

|

|


 

|
|

|
|
Image: A 20-year-old seropositive student living in Daola, Côte d'Ivoire. March 22, 2017 © UNICEF/UNI173979/Marion.
|

|


 

|
|
|
Wednesday, July 11th, 2018

10:30 AM–12 PM EST

13th Floor Maurice Pate Conference Room, UNICEF House
|

|

|


 

|
|
Ensuring good health and promoting the well-being of young people, particularly adolescent girls and young women, is essential to achieving the global sustainable development goals. Strategic integrated programming on health issues, can offer an opportunity to address broader goals around education, gender equality, or access to economic resources. PEPFAR’s DREAMS partnership is a unique example of a large scale program that has an explicit focus on HIV risk reduction, with programming that aims to addresses both health and structural vulnerabilities among adolescent girls and young women. 

During this presentation, the Population Council team will share emerging lessons from their work around the DREAMS Partnership. They will highlight the characteristics, perspectives, and risk profiles of adolescent girls and young women (AGYW) and their male partners, considerations for expanding the HIV prevention package for AGYW, and insights on the implementation of this comprehensive HIV prevention intervention package.
 
Opening Remarks:
Roberto Benes, UNICEF Country Representative, Argentina

Presenters: 
Julie Pulerwitz, ScD – Director, HIV and AIDS Program
Sanyukta Mathur, DrPH – Project Director, DREAMS Implementation Science Research
Miriam Temin, MSc – Project Director, Building Capacity for DREAMS Girl Platforms

Discussants:
Chewe Luo, MD PhD, Associate Director, HIV/AIDS, HIV Section
Anju Malhotra, PhD, Principal Advisor, Gender & Development, Gender Section


Colleagues from Population Council will be joining the session. Meet us in the 13th Floor Conference Room or join us via Skype.

To secure a seat to attend in person, please RSVP no later than July 9th by sending an email to: 
Rosy Rustomji rrustomji@unicef.org
Mignonne Fowlis mfowlis@unicef.org
|

|


 

|
|
|
........................................................................................................

 

Join Skype Meeting      

 
Trouble Joining? Try Skype Web App 
 ........................................................................................................
Join by phone
United States : +16467571480 (Global)            English (United States)
Switzerland : +41225083200 (Global)               English (United States)  
Hungary : +3617909400 (Global)                      English (United States)  
United Kingdom : +443300102423 (Global)     English (United Kingdom)  
Jordan : +96265509679 (Global)                      Arabic (Saudi Arabia)  
Panama : +5073017399 (Global)                      English (United States)  
Cambodia : +85523260206 (Global)                 English (United Kingdom)  
South Africa : +27879403508 (Global)             English (United Kingdom)  
Bulgaria : +35924928220 (Global)                    English (United Kingdom)  
Denmark : +4578793993 (Global)                     English (United States)  
France : +33176542732 (Global)                      French (France)  
Netherlands : +31705680050 (Global)              English (United States)  
Australia : +61730628687 (Global)                   English (Australia)  
Brazil : +556136860910 (Global)                      Portuguese (Brazil)  
Belgium : +3228080292 (Global)                      French (France)  
Greece : +302112340307 (Global)                   English (United Kingdom)  
Italy : +390697632494 (Global)                        Italian (Italy)  
Italy : +390552033399 (Global)                        Italian (Italy)  
Albania : +35544548424 (Global)                     English (United Kingdom)  
Moldova :  +37322893037 (Global)                  English (United States)  
Georgia : +995322422802 (Global)                  English (United Kingdom)  
Ukraine : +380443922163 (Global)                  Ukrainian (Ukraine)  
Austria : +43720775772 (Global)                      German (Germany)  
Turkey : +902127055614 (Global)                    Turkish (Turkey)  
Thailand: +6623049399 (Global)                      English (United States)  
Serbia : +381114410154 (Global)                     English (United Kingdom)  
Azerbaijan (pilot) : +994123105042 (Global)    English (United Kingdom)  
UNICEF VOIP: 4103010000 (Global)               English (United Kingdom)  
 
Find a local number

Conference ID: 759101139
Forgot your dial-in PIN? |Help  
 
 
 
|

|

|



|
|
| |


 

| |



|
|
|
| |

|


 

|
|

|

|


 

|
|
Children and AIDS Site
|

|



|

|


 

 

Jessica Rodrigues, MS

Programme Specialist (Partnerships and Learning)

UNICEF, HIV Section

3 UN Plaza

917 265-4533

 



 

 

Please visit the Children and AIDS community homepage to view discussion archives, library, and more! http://knowledge-gateway.org/childrenandaids

You are receiving this message because you are a member of the community Children and AIDS.

View this contribution on the web site

A reply to this message will be sent to all members of Children and AIDS.

Reply to sender | Unsubscribe

New Point-of-Care Early Infant Diagnosis Briefs

3 months ago
thanks!

Maurice MUDIMBE KALUNGU Directeur Exécutif National de la COPDECO-ONGD Tél.:+243-998123505; +243-817660960

Le mercredi 21 novembre 2018 à 16:33:25 UTC+1, Children and AIDS <cmannikarottu@unicef.org> a écrit :


|
|
|
|

|

|


 

|
|
UNICEF Learning Collaborative

is pleased to share with you


Two New Briefs on

Point-of-Care Early Infant Diagnosis of HIV
|

|


| |


 

|
|
|

|


|
This brief provides the most updated data, information and evidence on point-of-care early infant diagnosis as a game changer for the elimination of paediatric AIDS.

Available in Englishand French.
|

|

|
| |
|
|
|

|


|
This brief highlights different implementation approaches and testing strategies to expand access to point-of-care early infant diagnosis through both prevention of mother-to-child transmission (PMTCT) platforms and alternate entry points.
 

Available in Englishand French.
|

|

|
|
|

|

|
|
| |

|



|
|
| |


 

| |



|
|
|
|

|

|


 

|
|
Children and AIDS Site
|

|



|

|


 

 

 

 

 

Carthi Mannikarottu

HIV and AIDS Section, Programme Division

United Nations Children’s Fund

3 UN Plaza, New York NY 10017

cmannikarottu@unicef.org

Please visit the Children and AIDS community homepage to view discussion archives, library, and more! http://knowledge-gateway.org/childrenandaids

You are receiving this message because you are a member of the community Children and AIDS.

View this contribution on the web site

A reply to this message will be sent to all members of Children and AIDS.

Reply to sender | Unsubscribe

Highlights from CROI 2019

3 months ago
Enviado desde mi Samsung Mobile de Claro


-------- Mensaje original --------
De: Children and AIDS <cmannikarottu@unicef.org>
Fecha: 11/3/19 7:40 a. m. (GMT-05:00)
A: Children and AIDS <childrenandaids@knowledge-gateway.org>
Asunto: [childrenandaids] Highlights from CROI 2019


[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/e02d8cd9-f675-4eb8-b70a-d1b786512ff8.png]





UNICEF Learning Collaborative
is pleased to share




Conference Highlights from CROI 2019


[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/0d5ca0ff-2d66-41c1-b37f-1350f3bf9a0e.png]<http://www.croiconference.org/>


The Conference on Retroviruses and Opportunistic Infections (CROI)<http://www.croiconference.org/>, held last week in Seattle, brought together researchers from around the world to share the latest science and important developments in HIV/AIDS and related infectious diseases.
Highlights in research for pregnant women, children and adolescents living with HIV include:



* Sustained HIV-1 remission following homozygous CCR5 delt32 allogeneic HSCT: Gupta et al. presented the case of the “London Patient”, an HIV-positive man with no detectable HIV after receiving a bone marrow transplant with a had a double CCR5-delta-32 mutation to treat lymphoma. The man stopped antiretroviral therapy (ART) 16 months after the transplant and his viral load has remained undetectable 18 months since then. The researchers noted that cases of prolonged remission offer critical lessons in the search for an HIV cure. View the abstract<http://www.croiconference.org/sessions/sustained-hiv-1-remission-following-homozygous-ccr5-delta32-allogenic-hsct> and webcast<http://www.croiwebcasts.org/console/player/41065?mediaType=slideVideo&>.
* Point-of-care viral load testing improves HIV viral suppression and retention in care: Drain et al. presented results from a randomized controlled trial to test the impact of point-of-care (POC) viral load testing on achieving viral load suppression and retention in care for people living with HIV in Durban, South Africa. In the study, patients who received same-day results of a POC test had a 14 per cent improvement in virological suppression and retention in care compared to those who waited weeks for their results from standard laboratory testing. View the abstract<http://www.croiconference.org/sessions/point-care-viral-load-testing-improves-hiv-viral-suppression-and-retention-care> and webcast<http://www.croiwebcasts.org/console/player/41097?mediaType=slideVideo&>.
* Randomized trial of raltegravir-ART vs efavirenz-ART when initiated during pregnancy: The NICHD P1081 trial, carried out in South America, Africa, Thailand and the United States, randomized pregnant women to receive either raltegravir- or efavirenz-based ART. Mirochnick et al. presented results of the trial that support the use of raltegravir for women starting ART later in pregnancy. Significantly more women receiving raltegravir had a viral load below 200 copies/ml at delivery than women receiving efavirenz (94% vs 84%) with the strongest associations among women who started ART after week 28 of pregnancy. View the abstract<http://www.croiconference.org/sessions/randomized-trial-raltegravir-art-vs-efavirenz-art-when-initiated-during-pregnancy> and webcast<http://www.croiwebcasts.org/console/player/41080?mediaType=audio&>.
* RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: Results from the DOLPHIN-2 trial, presented by Khoo et al., also supported the use of integrase inhibitors during pregnancy. The trial, carried out in Uganda and South Africa, randomized pregnant women to receive either dolutegravir- or efavirenz-based ART. Significantly more women in the dolutegravir arm had a viral load below 50 copies/ml at delivery than in the efavirenz arm (73.8% vs 42.6%). Viral loads of less than 1,000 copies/mL at delivery was seen in 93 per cent of women receiving dolutegravir and 83 per cent of women on efavirenz. View the abstract<http://www.croiconference.org/sessions/rct-dolutegravir-vs-efavirenz-based-therapy-initiated-late-pregnancy-dolphin-2> and webcast<http://www.croiwebcasts.org/console/player/41081?mediaType=audio&>.
* A randomized trial on index HIV self-testing for partners of ART clients in Malawi: A study conducted in district hospitals in Malawi found that people living with HIV who distributed HIV self-test kids to their sexual partners increased testing uptake without adverse effects on their relationships. Dovel et al. presented results from the study, which included 365 participants aged 15 and older. Testing uptake was 73 per cent in the self-testing arm compared to 27 per cent in the arm that received standard partner referral slips. View the abstract<http://www.croiconference.org/sessions/randomized-trial-index-hiv-self-testing-partners-art-clients-malawi> and webcast<http://www.croiwebcasts.org/console/player/41196?mediaType=audio&>.



Save the Date: Webinar on CROI 2019


UNICEF Learning Collaborative invites you to a webinar with curated research from CROI 2019 and its implications.

Dr. Lynne Mofenson will present an overview of the latest science related to HIV, women, children and adolescents on Monday April 1, 2019 at 9 am EDT. The webinar will be one hour with time for Q&A and discussion.

Stay tuned for more details.





[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/4752c44e-7697-48ef-ba69-6f11f890566c.png]







Children and AIDS Site<http://www.childrenandaids.org/>






Carthi Mannikarottu
HIV and AIDS Section, Programme Division
United Nations Children’s Fund
3 UN Plaza, New York NY 10017
cmannikarottu@unicef.org<mailto:cmannikarottu@unicef.org>

[Children & AIDS]
[cid:image001.png@01D277D4.60EBBD80]


Please visit the Children and AIDS community homepage to view discussion archives, library, and more! http://knowledge-gateway.org/childrenandaids

You are receiving this message because you are a member of the community Children and AIDS<https://knowledge-gateway.org/childrenandaids>.

View this contribution on the web site<https://knowledge-gateway.org/_/6p0tf3mc>

A reply to this message will be sent to all members of Children and AIDS.

Reply to sender<mailto:cmannikarottu@unicef.org> | Unsubscribe<mailto:leave.childrenandaids@knowledge-gateway.org>

Highlights from CROI 2019

3 months ago
Bjnxdc GB no

Dr gOlufemi Adeyemi🍘 x xx h r
Health Specialist
I v mp Field Office
+234 706 410 2813
________________________________
From: Children and AIDS<mailto:cmannikarottu@unicef.org>
Sent: ‎3/‎11/‎2019 1:40 PM
To: Children and AIDS<mailto:childrenandaids@knowledge-gateway.org>
Subject: [childrenandaids] Highlights from CROI 2019


[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/e02d8cd9-f675-4eb8-b70a-d1b786512ff8.png]





UNICEF Learning Collaborative
is pleased to share




Conference Highlights from CROI 2019


[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/0d5ca0ff-2d66-41c1-b37f-1350f3bf9a0e.png]<http://www.croiconference.org/>


The Conference on Retroviruses and Opportunistic Infections (CROI)<http://www.croiconference.org/>, held last week in Seattle, brought together researchers from around the world to share the latest science and important developments in HIV/AIDS and related infectious diseases.
Highlights in research for pregnant women, children and adolescents living with HIV include:



* Sustained HIV-1 remission following homozygous CCR5 delt32 allogeneic HSCT: Gupta et al. presented the case of the “London Patient”, an HIV-positive man with no detectable HIV after receiving a bone marrow transplant with a had a double CCR5-delta-32 mutation to treat lymphoma. The man stopped antiretroviral therapy (ART) 16 months after the transplant and his viral load has remained undetectable 18 months since then. The researchers noted that cases of prolonged remission offer critical lessons in the search for an HIV cure. View the abstract<http://www.croiconference.org/sessions/sustained-hiv-1-remission-following-homozygous-ccr5-delta32-allogenic-hsct> and webcast<http://www.croiwebcasts.org/console/player/41065?mediaType=slideVideo&>.
* Point-of-care viral load testing improves HIV viral suppression and retention in care: Drain et al. presented results from a randomized controlled trial to test the impact of point-of-care (POC) viral load testing on achieving viral load suppression and retention in care for people living with HIV in Durban, South Africa. In the study, patients who received same-day results of a POC test had a 14 per cent improvement in virological suppression and retention in care compared to those who waited weeks for their results from standard laboratory testing. View the abstract<http://www.croiconference.org/sessions/point-care-viral-load-testing-improves-hiv-viral-suppression-and-retention-care> and webcast<http://www.croiwebcasts.org/console/player/41097?mediaType=slideVideo&>.
* Randomized trial of raltegravir-ART vs efavirenz-ART when initiated during pregnancy: The NICHD P1081 trial, carried out in South America, Africa, Thailand and the United States, randomized pregnant women to receive either raltegravir- or efavirenz-based ART. Mirochnick et al. presented results of the trial that support the use of raltegravir for women starting ART later in pregnancy. Significantly more women receiving raltegravir had a viral load below 200 copies/ml at delivery than women receiving efavirenz (94% vs 84%) with the strongest associations among women who started ART after week 28 of pregnancy. View the abstract<http://www.croiconference.org/sessions/randomized-trial-raltegravir-art-vs-efavirenz-art-when-initiated-during-pregnancy> and webcast<http://www.croiwebcasts.org/console/player/41080?mediaType=audio&>.
* RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: Results from the DOLPHIN-2 trial, presented by Khoo et al., also supported the use of integrase inhibitors during pregnancy. The trial, carried out in Uganda and South Africa, randomized pregnant women to receive either dolutegravir- or efavirenz-based ART. Significantly more women in the dolutegravir arm had a viral load below 50 copies/ml at delivery than in the efavirenz arm (73.8% vs 42.6%). Viral loads of less than 1,000 copies/mL at delivery was seen in 93 per cent of women receiving dolutegravir and 83 per cent of women on efavirenz. View the abstract<http://www.croiconference.org/sessions/rct-dolutegravir-vs-efavirenz-based-therapy-initiated-late-pregnancy-dolphin-2> and webcast<http://www.croiwebcasts.org/console/player/41081?mediaType=audio&>.
* A randomized trial on index HIV self-testing for partners of ART clients in Malawi: A study conducted in district hospitals in Malawi found that people living with HIV who distributed HIV self-test kids to their sexual partners increased testing uptake without adverse effects on their relationships. Dovel et al. presented results from the study, which included 365 participants aged 15 and older. Testing uptake was 73 per cent in the self-testing arm compared to 27 per cent in the arm that received standard partner referral slips. View the abstract<http://www.croiconference.org/sessions/randomized-trial-index-hiv-self-testing-partners-art-clients-malawi> and webcast<http://www.croiwebcasts.org/console/player/41196?mediaType=audio&>.



Save the Date: Webinar on CROI 2019


UNICEF Learning Collaborative invites you to a webinar with curated research from CROI 2019 and its implications.

Dr. Lynne Mofenson will present an overview of the latest science related to HIV, women, children and adolescents on Monday April 1, 2019 at 9 am EDT. The webinar will be one hour with time for Q&A and discussion.

Stay tuned for more details.





[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/4752c44e-7697-48ef-ba69-6f11f890566c.png]







Children and AIDS Site<http://www.childrenandaids.org/>






Carthi Mannikarottu
HIV and AIDS Section, Programme Division
United Nations Children’s Fund
3 UN Plaza, New York NY 10017
cmannikarottu@unicef.org<mailto:cmannikarottu@unicef.org>

[Children & AIDS]
[cid:image001.png@01D277D4.60EBBD80]


Please visit the Children and AIDS community homepage to view discussion archives, library, and more! http://knowledge-gateway.org/childrenandaids

You are receiving this message because you are a member of the community Children and AIDS<https://knowledge-gateway.org/childrenandaids>.

View this contribution on the web site<https://knowledge-gateway.org/_/6p0tf3mc>

A reply to this message will be sent to all members of Children and AIDS.

Reply to sender<mailto:cmannikarottu@unicef.org> | Unsubscribe<mailto:leave.childrenandaids@knowledge-gateway.org>

Highlights from CROI 2019

3 months ago
Hello Carthi,

Well received. 
Thank you.
Regards,

Martial Elvis SEMONDJI, MD, MBA

Health Economist(221) 77 769 29 65

Le lundi 11 mars 2019 à 12:39:37 UTC, Children and AIDS <cmannikarottu@unicef.org> a écrit :

<!--#yiv0345294596 _filtered #yiv0345294596 {font-family:Helvetica;panose-1:2 11 6 4 2 2 2 2 2 4;} _filtered #yiv0345294596 {font-family:Wingdings;panose-1:5 0 0 0 0 0 0 0 0 0;} _filtered #yiv0345294596 {font-family:"Cambria Math";panose-1:2 4 5 3 5 4 6 3 2 4;} _filtered #yiv0345294596 {font-family:Calibri;panose-1:2 15 5 2 2 2 4 3 2 4;} _filtered #yiv0345294596 {font-family:Roboto;panose-1:2 0 0 0 0 0 0 0 0 0;}#yiv0345294596 #yiv0345294596 p.yiv0345294596MsoNormal, #yiv0345294596 li.yiv0345294596MsoNormal, #yiv0345294596 div.yiv0345294596MsoNormal {margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri", sans-serif;}#yiv0345294596 h2 {margin-right:0in;margin-left:0in;font-size:18.0pt;font-family:"Times New Roman", serif;font-weight:bold;}#yiv0345294596 a:link, #yiv0345294596 span.yiv0345294596MsoHyperlink {color:#0563C1;text-decoration:underline;}#yiv0345294596 a:visited, #yiv0345294596 span.yiv0345294596MsoHyperlinkFollowed {color:#954F72;text-decoration:underline;}#yiv0345294596 p {margin-right:0in;margin-left:0in;font-size:12.0pt;font-family:"Times New Roman", serif;}#yiv0345294596 span.yiv0345294596Heading2Char {font-family:"Times New Roman", serif;font-weight:bold;}#yiv0345294596 span.yiv0345294596EmailStyle19 {font-family:"Calibri", sans-serif;color:windowtext;}#yiv0345294596 .yiv0345294596MsoChpDefault {font-size:10.0pt;font-family:"Calibri", sans-serif;} _filtered #yiv0345294596 {margin:1.0in 1.0in 1.0in 1.0in;}#yiv0345294596 div.yiv0345294596WordSection1 {}#yiv0345294596 _filtered #yiv0345294596 {} _filtered #yiv0345294596 {font-family:Symbol;} _filtered #yiv0345294596 {font-family:Symbol;} _filtered #yiv0345294596 {font-family:Symbol;} _filtered #yiv0345294596 {font-family:Symbol;} _filtered #yiv0345294596 {font-family:Symbol;} _filtered #yiv0345294596 {font-family:Symbol;} _filtered #yiv0345294596 {font-family:Symbol;} _filtered #yiv0345294596 {font-family:Symbol;} _filtered #yiv0345294596 {font-family:Symbol;} _filtered #yiv0345294596 {} _filtered #yiv0345294596 {font-family:Symbol;} _filtered #yiv0345294596 {font-family:"Courier New";} _filtered #yiv0345294596 {font-family:Wingdings;} _filtered #yiv0345294596 {font-family:Wingdings;} _filtered #yiv0345294596 {font-family:Wingdings;} _filtered #yiv0345294596 {font-family:Wingdings;} _filtered #yiv0345294596 {font-family:Wingdings;} _filtered #yiv0345294596 {font-family:Wingdings;} _filtered #yiv0345294596 {font-family:Wingdings;}#yiv0345294596 ol {margin-bottom:0in;}#yiv0345294596 ul {margin-bottom:0in;}-->
 

|
|
|
|

|

|


 

| |
|
|

UNICEF Learning Collaborative
is pleased to share
|

|
|
| |

|
|
|
Conference Highlights from CROI 2019
|

|
|
|

|
|
The Conference on Retroviruses and Opportunistic Infections (CROI), held last week in Seattle, brought together researchers from around the world to share the latest science and important developments in HIV/AIDS and related infectious diseases.

Highlights in research for pregnant women, children and adolescents living with HIV include:
|

|
|
|
- Sustained HIV-1 remission following homozygous CCR5 delt32 allogeneic HSCT: Gupta et al. presented the case of the “London Patient”, an HIV-positive man with no detectable HIV after receiving a bone marrow transplant with a had a double CCR5-delta-32 mutation to treat lymphoma. The man stopped antiretroviral therapy (ART) 16 months after the transplant and his viral load has remained undetectable 18 months since then. The researchers noted that cases of prolonged remission offer critical lessons in the search for an HIV cure. View the abstract andwebcast.  
- Point-of-care viral load testing improves HIV viral suppression and retention in care: Drain et al. presented results from a randomized controlled trial to test the impact of point-of-care (POC) viral load testing on achieving viral load suppression and retention in care for people living with HIV in Durban, South Africa. In the study, patients who received same-day results of a POC test had a 14 per cent improvement in virological suppression and retention in care compared to those who waited weeks for their results from standard laboratory testing. View the abstract andwebcast.
- Randomized trial of raltegravir-ART vs efavirenz-ART when initiated during pregnancy: The NICHD P1081 trial, carried out in South America, Africa, Thailand and the United States, randomized pregnant women to receive either raltegravir- or efavirenz-based ART. Mirochnick et al. presented results of the trial that support the use of raltegravir for women starting ART later in pregnancy. Significantly more women receiving raltegravir had a viral load below 200 copies/ml at delivery than women receiving efavirenz (94% vs 84%) with the strongest associations among women who started ART after week 28 of pregnancy. View the abstract and webcast.
- RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: Results from the DOLPHIN-2 trial, presented by Khoo et al., also supported the use of integrase inhibitors during pregnancy. The trial, carried out in Uganda and South Africa, randomized pregnant women to receive either dolutegravir- or efavirenz-based ART. Significantly more women in the dolutegravir arm had a viral load below 50 copies/ml at delivery than in the efavirenz arm (73.8% vs 42.6%). Viral loads of less than 1,000 copies/mL at delivery was seen in 93 per cent of women receiving dolutegravir and 83 per cent of women on efavirenz. View the abstract and webcast.
- A randomized trial on index HIV self-testing for partners of ART clients in Malawi: A study conducted in district hospitals in Malawi found that people living with HIV who distributed HIV self-test kids to their sexual partners increased testing uptake without adverse effects on their relationships. Dovel et al. presented results from the study, which included 365 participants aged 15 and older. Testing uptake was 73 per cent in the self-testing arm compared to 27 per cent in the arm that received standard partner referral slips. View the abstract and webcast.  
|

|
|
|
Save the Date: Webinar on CROI 2019
|

|
|
|
|
UNICEF Learning Collaborative invites you to a webinar with curated research from CROI 2019 and its implications.

Dr. Lynne Mofenson will present an overview of the latest science related to HIV, women, children and adolescents on Monday April 1, 2019 at 9 am EDT. The webinar will be one hour with time for Q&A and discussion. 

Stay tuned for more details.
|

|

|
|
| |

|
|
|

|

|



|
|
| |


 

| |



|
|
|
|
Children and AIDS Site
|

|

|

|


 

 

Carthi Mannikarottu

HIV and AIDS Section, Programme Division

United Nations Children’s Fund

3 UN Plaza, New York NY 10017

cmannikarottu@unicef.org

 





 

Please visit the Children and AIDS community homepage to view discussion archives, library, and more! http://knowledge-gateway.org/childrenandaids

You are receiving this message because you are a member of the community Children and AIDS.

View this contribution on the web site

A reply to this message will be sent to all members of Children and AIDS.

Reply to sender | Unsubscribe

Highlights from CROI 2019

3 months ago
Merci de cet envoi

Best Regards

Le lun. 11 mars 2019 à 12:39, Children and AIDS <cmannikarottu@unicef.org>
a écrit :

>
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/e02d8cd9-f675-4eb8-b70a-d1b786512ff8.png]
>
>
>
> UNICEF Learning Collaborative
> is pleased to share
> Conference Highlights from CROI 2019
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/0d5ca0ff-2d66-41c1-b37f-1350f3bf9a0e.png]
> <http://www.croiconference.org/>
>
> The *Conference on Retroviruses and Opportunistic Infections (CROI)*
> <http://www.croiconference.org/>, held last week in Seattle, brought
> together researchers from around the world to share the latest science
> and important developments in HIV/AIDS and related infectious diseases.
>
> Highlights in research for pregnant women, children and adolescents living
> with HIV include:
>
> - *Sustained HIV-1 remission following homozygous CCR5 delt32
> allogeneic HSCT:* Gupta et al. presented the case of the “London
> Patient”, an HIV-positive man with no detectable HIV after receiving a bone
> marrow transplant with a had a double CCR5-delta-32 mutation to treat
> lymphoma. The man stopped antiretroviral therapy (ART) 16 months after the
> transplant and his viral load has remained undetectable 18 months since
> then. The researchers noted that cases of prolonged remission offer
> critical lessons in the search for an HIV cure. View the *abstract*
> <http://www.croiconference.org/sessions/sustained-hiv-1-remission-following-homozygous-ccr5-delta32-allogenic-hsct> and
> *webcast*
> <http://www.croiwebcasts.org/console/player/41065?mediaType=slideVideo&>.
>
> - *Point-of-care viral load testing improves HIV viral suppression and
> retention in care:* Drain et al. presented results from a randomized
> controlled trial to test the impact of point-of-care (POC) viral load
> testing on achieving viral load suppression and retention in care for
> people living with HIV in Durban, South Africa. In the study, patients who
> received same-day results of a POC test had a 14 per cent improvement in
> virological suppression and retention in care compared to those who waited
> weeks for their results from standard laboratory testing. View the
> *abstract*
> <http://www.croiconference.org/sessions/point-care-viral-load-testing-improves-hiv-viral-suppression-and-retention-care> and
> *webcast*
> <http://www.croiwebcasts.org/console/player/41097?mediaType=slideVideo&>
> .
> - *Randomized trial of raltegravir-ART vs efavirenz-ART when initiated
> during pregnancy: *The NICHD P1081 trial, carried out in South
> America, Africa, Thailand and the United States, randomized pregnant women
> to receive either raltegravir- or efavirenz-based ART. Mirochnick et al.
> presented results of the trial that support the use of raltegravir for
> women starting ART later in pregnancy. Significantly more women receiving
> raltegravir had a viral load below 200 copies/ml at delivery than women
> receiving efavirenz (94% vs 84%) with the strongest associations among
> women who started ART after week 28 of pregnancy. View the *abstract*
> <http://www.croiconference.org/sessions/randomized-trial-raltegravir-art-vs-efavirenz-art-when-initiated-during-pregnancy> and
> *webcast*
> <http://www.croiwebcasts.org/console/player/41080?mediaType=audio&>.
> - *RCT of dolutegravir vs efavirenz-based therapy initiated in late
> pregnancy: *Results from the DOLPHIN-2 trial, presented by Khoo et
> al., also supported the use of integrase inhibitors during pregnancy. The
> trial, carried out in Uganda and South Africa, randomized pregnant women to
> receive either dolutegravir- or efavirenz-based ART. Significantly more
> women in the dolutegravir arm had a viral load below 50 copies/ml at
> delivery than in the efavirenz arm (73.8% vs 42.6%). Viral loads of less
> than 1,000 copies/mL at delivery was seen in 93 per cent of women receiving
> dolutegravir and 83 per cent of women on efavirenz. View the *abstract*
> <http://www.croiconference.org/sessions/rct-dolutegravir-vs-efavirenz-based-therapy-initiated-late-pregnancy-dolphin-2>
> and *webcast*
> <http://www.croiwebcasts.org/console/player/41081?mediaType=audio&>.
> - *A randomized trial on index HIV self-testing for partners of ART
> clients in Malawi: *A study conducted in district hospitals in Malawi
> found that people living with HIV who distributed HIV self-test kids to
> their sexual partners increased testing uptake without adverse effects on
> their relationships. Dovel et al. presented results from the study, which
> included 365 participants aged 15 and older. Testing uptake was 73 per cent
> in the self-testing arm compared to 27 per cent in the arm that received
> standard partner referral slips. View the *abstract*
> <http://www.croiconference.org/sessions/randomized-trial-index-hiv-self-testing-partners-art-clients-malawi>
> and *webcast*
> <http://www.croiwebcasts.org/console/player/41196?mediaType=audio&>.
>
> Save the Date: Webinar on CROI 2019
>
> UNICEF Learning Collaborative invites you to a webinar with curated
> research from CROI 2019 and its implications.
>
> *Dr. Lynne Mofenson* will present an overview of the latest science
> related to HIV, women, children and adolescents on *Monday April 1, 2019 *
> at *9 am EDT*. The webinar will be one hour with time for Q&A and
> discussion.
>
> Stay tuned for more details.
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/4752c44e-7697-48ef-ba69-6f11f890566c.png]
>
>
>
> *Children and AIDS Site* <http://www.childrenandaids.org/>
>
>
>
>
>
> *Carthi Mannikarottu*
>
> HIV and AIDS Section, Programme Division
>
> United Nations Children’s Fund
>
> 3 UN Plaza, New York NY 10017
>
> cmannikarottu@unicef.org
>
>
>
> [image: Children & AIDS]
>
> [image: cid:image001.png@01D277D4.60EBBD80]
>
>
>
> Please visit the Children and AIDS community homepage to view discussion
> archives, library, and more! http://knowledge-gateway.org/childrenandaids
>
> You are receiving this message because you are a member of the community Children
> and AIDS <https://knowledge-gateway.org/childrenandaids>.
>
> View this contribution on the web site
> <https://knowledge-gateway.org/_/6p0tf3mc>
>
> A reply to this message will be sent to all members of Children and AIDS.
>
> Reply to sender <cmannikarottu@unicef.org> | Unsubscribe
> <leave.childrenandaids@knowledge-gateway.org>
>


--

*Pierre Claver BONI A.*

Assistant Site/District sanitaire Bouaké SUD

*+*225 79559133 (Mobile)*|**perrieclevar@yahoo.fr*
<%7Cperrieclevar@yahoo.fr>

+225 79490953 (Office)*|cboni@ccp.ci <%7Ccboni@ccp.ci>*

Skype: clevar 7

*www.breakthroughactionandresearch.org
<http://www.breakthroughactionandresearch.org/>*

*https://www.facebook.com/JHUCCP.Cotedivoire/
<https://www.facebook.com/JHUCCP.Cotedivoire/>*

Highlights from CROI 2019

3 months ago
Thank and well received.

-----Original Message-----
From: "Children and AIDS" <cmannikarottu@unicef.org>
Sent: ‎11/‎03/‎2019 14:39
To: "Children and AIDS" <childrenandaids@knowledge-gateway.org>
Subject: [childrenandaids] Highlights from CROI 2019








UNICEF Learning Collaborative
is pleased to share



Conference Highlights from CROI 2019


The Conference on Retroviruses and Opportunistic Infections (CROI), held last week in Seattle, brought together researchers from around the world to share the latest science and important developments in HIV/AIDS and related infectious diseases.
Highlights in research for pregnant women, children and adolescents living with HIV include:

Sustained HIV-1 remission following homozygous CCR5 delt32 allogeneic HSCT: Gupta et al. presented the case of the “London Patient”, an HIV-positive man with no detectable HIV after receiving a bone marrow transplant with a had a double CCR5-delta-32 mutation to treat lymphoma. The man stopped antiretroviral therapy (ART) 16 months after the transplant and his viral load has remained undetectable 18 months since then. The researchers noted that cases of prolonged remission offer critical lessons in the search for an HIV cure. View the abstract and webcast.
Point-of-care viral load testing improves HIV viral suppression and retention in care: Drain et al. presented results from a randomized controlled trial to test the impact of point-of-care (POC) viral load testing on achieving viral load suppression and retention in care for people living with HIV in Durban, South Africa. In the study, patients who received same-day results of a POC test had a 14 per cent improvement in virological suppression and retention in care compared to those who waited weeks for their results from standard laboratory testing. View the abstract and webcast.
Randomized trial of raltegravir-ART vs efavirenz-ART when initiated during pregnancy: The NICHD P1081 trial, carried out in South America, Africa, Thailand and the United States, randomized pregnant women to receive either raltegravir- or efavirenz-based ART. Mirochnick et al. presented results of the trial that support the use of raltegravir for women starting ART later in pregnancy. Significantly more women receiving raltegravir had a viral load below 200 copies/ml at delivery than women receiving efavirenz (94% vs 84%) with the strongest associations among women who started ART after week 28 of pregnancy. View the abstract and webcast.
RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: Results from the DOLPHIN-2 trial, presented by Khoo et al., also supported the use of integrase inhibitors during pregnancy. The trial, carried out in Uganda and South Africa, randomized pregnant women to receive either dolutegravir- or efavirenz-based ART. Significantly more women in the dolutegravir arm had a viral load below 50 copies/ml at delivery than in the efavirenz arm (73.8% vs 42.6%). Viral loads of less than 1,000 copies/mL at delivery was seen in 93 per cent of women receiving dolutegravir and 83 per cent of women on efavirenz. View the abstract and webcast.
A randomized trial on index HIV self-testing for partners of ART clients in Malawi: A study conducted in district hospitals in Malawi found that people living with HIV who distributed HIV self-test kids to their sexual partners increased testing uptake without adverse effects on their relationships. Dovel et al. presented results from the study, which included 365 participants aged 15 and older. Testing uptake was 73 per cent in the self-testing arm compared to 27 per cent in the arm that received standard partner referral slips. View the abstract and webcast.


<table class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0" align="left" width="100%" style="width:100.0%;border-collapse:

[The entire original message is not included.]

Highlights from CROI 2019

3 months 1 week ago
[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/e02d8cd9-f675-4eb8-b70a-d1b786512ff8.png]





UNICEF Learning Collaborative
is pleased to share




Conference Highlights from CROI 2019


[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/0d5ca0ff-2d66-41c1-b37f-1350f3bf9a0e.png]<http://www.croiconference.org/>


The Conference on Retroviruses and Opportunistic Infections (CROI)<http://www.croiconference.org/>, held last week in Seattle, brought together researchers from around the world to share the latest science and important developments in HIV/AIDS and related infectious diseases.
Highlights in research for pregnant women, children and adolescents living with HIV include:



* Sustained HIV-1 remission following homozygous CCR5 delt32 allogeneic HSCT: Gupta et al. presented the case of the "London Patient", an HIV-positive man with no detectable HIV after receiving a bone marrow transplant with a had a double CCR5-delta-32 mutation to treat lymphoma. The man stopped antiretroviral therapy (ART) 16 months after the transplant and his viral load has remained undetectable 18 months since then. The researchers noted that cases of prolonged remission offer critical lessons in the search for an HIV cure. View the abstract<http://www.croiconference.org/sessions/sustained-hiv-1-remission-following-homozygous-ccr5-delta32-allogenic-hsct> and webcast<http://www.croiwebcasts.org/console/player/41065?mediaType=slideVideo&>.
* Point-of-care viral load testing improves HIV viral suppression and retention in care: Drain et al. presented results from a randomized controlled trial to test the impact of point-of-care (POC) viral load testing on achieving viral load suppression and retention in care for people living with HIV in Durban, South Africa. In the study, patients who received same-day results of a POC test had a 14 per cent improvement in virological suppression and retention in care compared to those who waited weeks for their results from standard laboratory testing. View the abstract<http://www.croiconference.org/sessions/point-care-viral-load-testing-improves-hiv-viral-suppression-and-retention-care> and webcast<http://www.croiwebcasts.org/console/player/41097?mediaType=slideVideo&>.
* Randomized trial of raltegravir-ART vs efavirenz-ART when initiated during pregnancy: The NICHD P1081 trial, carried out in South America, Africa, Thailand and the United States, randomized pregnant women to receive either raltegravir- or efavirenz-based ART. Mirochnick et al. presented results of the trial that support the use of raltegravir for women starting ART later in pregnancy. Significantly more women receiving raltegravir had a viral load below 200 copies/ml at delivery than women receiving efavirenz (94% vs 84%) with the strongest associations among women who started ART after week 28 of pregnancy. View the abstract<http://www.croiconference.org/sessions/randomized-trial-raltegravir-art-vs-efavirenz-art-when-initiated-during-pregnancy> and webcast<http://www.croiwebcasts.org/console/player/41080?mediaType=audio&>.
* RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: Results from the DOLPHIN-2 trial, presented by Khoo et al., also supported the use of integrase inhibitors during pregnancy. The trial, carried out in Uganda and South Africa, randomized pregnant women to receive either dolutegravir- or efavirenz-based ART. Significantly more women in the dolutegravir arm had a viral load below 50 copies/ml at delivery than in the efavirenz arm (73.8% vs 42.6%). Viral loads of less than 1,000 copies/mL at delivery was seen in 93 per cent of women receiving dolutegravir and 83 per cent of women on efavirenz. View the abstract<http://www.croiconference.org/sessions/rct-dolutegravir-vs-efavirenz-based-therapy-initiated-late-pregnancy-dolphin-2> and webcast<http://www.croiwebcasts.org/console/player/41081?mediaType=audio&>.
* A randomized trial on index HIV self-testing for partners of ART clients in Malawi: A study conducted in district hospitals in Malawi found that people living with HIV who distributed HIV self-test kids to their sexual partners increased testing uptake without adverse effects on their relationships. Dovel et al. presented results from the study, which included 365 participants aged 15 and older. Testing uptake was 73 per cent in the self-testing arm compared to 27 per cent in the arm that received standard partner referral slips. View the abstract<http://www.croiconference.org/sessions/randomized-trial-index-hiv-self-testing-partners-art-clients-malawi> and webcast<http://www.croiwebcasts.org/console/player/41196?mediaType=audio&>.



Save the Date: Webinar on CROI 2019


UNICEF Learning Collaborative invites you to a webinar with curated research from CROI 2019 and its implications.

Dr. Lynne Mofenson will present an overview of the latest science related to HIV, women, children and adolescents on Monday April 1, 2019 at 9 am EDT. The webinar will be one hour with time for Q&A and discussion.

Stay tuned for more details.





[https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/4752c44e-7697-48ef-ba69-6f11f890566c.png]







Children and AIDS Site<http://www.childrenandaids.org/>






Carthi Mannikarottu
HIV and AIDS Section, Programme Division
United Nations Children's Fund
3 UN Plaza, New York NY 10017
cmannikarottu@unicef.org<mailto:cmannikarottu@unicef.org>

[Children & AIDS]
[cid:image001.png@01D277D4.60EBBD80]

ASLM POC News Digest August 2018

3 months 1 week ago
ASLM POC News Digest August 2018 ASLM POC News Digest August 2018 This month’s Point-of-Care News Digest focuses on the point-of-care best practices disseminated through ASLM’s Laboratory System Strengthening Community of Practice Project (LabCoP), the point-of-care recency testing, and a call for papers on AJLM’s special issue on the future of diagnostics. ASLM LabCoP ECHO Session: HIV Point-of-Care Integration and Viral Load Testing This month, Unitaid’s point-of-care (POC) team joined ASLM’s LabCoP team and 11 member countries for their monthly ECHO Session, a platform by which member countries engage in south-to-south information sharing about considerations and best practices related to viral load (VL) topics. The August ECHO session featured lessons learnt from the Unitaid-funded pilots of HIV POC testing integration and VL testing implemented across countries supported by CHAI/EGPAF/UNICEF. Jilian Sacks, HIV & HCV Scientist at CHAI presented about how certain populations (e.g. women who are HIV-positive and pregnant and/or breastfeeding, children and adolescents who are HIV-positive, those with advanced HIV) and those living in remote or conflict-ridden settings may be better served by accessing more rapid VL testing afforded through HIV POC tests. The group also discussed how integration of HIV, tuberculosis and VL tests on POC devices is an opportunity to increase access and minimize costs of POC testing. Countries agreed that product and site selection will be a pre-requisite to building an optimized VL testing network, and that robust, supportive systems, including strong training, quality management systems and supply chains, can ensure successful POC testing. “While centralized laboratory testing remains the backbone of VL testing, HIV POC is an innovative solution that complements conventional laboratory testing in order to address some of the existing testing gaps” said Mr. Charles Kiyaga, ASLM LabCoP Project Manager. Email Charles at Ckiyaga@aslm.org for more information about joining LabCoP. To view the video session, click here. Using Rapid Point-of-Care Tests to Detect Recency of an HIV Infection As many countries approach the tipping point of their HIV epidemics, continuous assessment of a population’s HIV epidemic through ongoing surveillance remains essential to ensure that interventions are efficiently and effectively targeting those at greatest risk of acquiring or transmitting HIV. A point-of-care recency test kit has been developed, that combines verifications of HIV diagnosis and detection of recent HIV-1 infection in one testing device, and is now available commercially. We put a spotlight on the Asante HIV-1 Rapid Recency Assay, an innovative rapid test for HIV diagnosis that can be applied in routine HIV testing services. The results can be returned to the tested client with appropriate counselling during the visit. Click here for more information. Call for Papers: AJLM Special Issue on The Future of Diagnostics In 2019, the African Journal of Laboratory Medicine (AJLM), will publish a special issue devoted to The Future of Diagnostics. This special issue will be co-edited by Professors Timothy Amukele (Johns Hopkins University School of Medicine), Ilesh Jani (Instituto Nacional de Saúde, Maputo, Mozambique) and Rosanna Peeling (London School of Hygiene and Tropical Medicine). The issue aims to highlight recent advances in technology and the landscape for diagnostic innovation. It will emphasise diagnostics for high burden, emerging and neglected communicable and non-communicable diseases, particularly those that threaten or are endemic to the African continent. AJLM invites submissions to The Future of Diagnostics that will document the promise of diagnostic development and push its boundaries. Click here for more information. ASLM’s Point-of-Care project is Supported by Unitaid and partners [United Nations Children's Fund (UNICEF), Clinton Health Access Initiative (CHAI), Elizabeth Glaser Paediatric AIDS Foundation (EGPAF)] August ECHO session on YouTube. Join us at www.ASLM2018.org 10-13 Dec 2018 Abuja. Nigeria Connect with us ‌ ‌ ‌ ASLM | www.ASLM.org, www.AJLMonline.org, www.aslm2018.org Addis Ababa Ethiopia Unsubscribe childrenandaids@knowledge-gateway.org Update Profile | About our service provider Sent by communication@aslm.org in collaboration with Try it free today

Webinar on WHO Update on the Use of ARVs for Preventing and Treating HIV Infection and Early Infant Diagnosis

3 months 1 week ago
Merci de cet envoi

Le jeu. 6 sept. 2018 à 14:10, Children and AIDS <jerodrigues@unicef.org> a
écrit :

>
>
>
>
>
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/e02d8cd9-f675-4eb8-b70a-d1b786512ff8.png]
>
>
>
> *UNICEF Learning Collaborative*
>
> *is pleased to invite you to a*
>
>
> *Webinar on the World Health Organization *
> *Update on the Use of ARVs for Preventing and Treating HIV Infection*
>
> *and Early Infant Diagnosis*
>
>
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/eaaedb66-8008-45d5-bf79-714eb6e5e1be.png]
>
>
>
> *Thursday, September 13th 2018*
>
> 8:30 AM–10:00 AM EST
>
> 10th Floor Conference Room
>
>
>
> This webinar will provide an overview of WHO's *Updated recommendations
> on first-line and second-line antiretroviral regimens and post-exposure
> prophylaxis and recommendations on early infant diagnosis of HIV: interim
> guidance.*
>
> Presenters include: *Meg Doherty, Martina Penazzato and Lara Vojnov of
> WHO, Elaine Abrams, ICAP, Shaffiq Essajee, UNICEF and country
> representatives to be determined. *
>
> You can join the meeting via *Skype*
> <https://meet.unicef.org/jerodrigues/H8VCHHY9> or join us in the 9th
> Floor Conference Room.
>
>
>
>
>
> [image:
> https://gallery.mailchimp.com/82682f0b9776eacd79feac406/images/af3a38ff-6e01-4998-a2d4-cc8917e28b1c.png]
>
>
>
> *Children and AIDS Site* <http://www.childrenandaids.org/>
>
>
>
>
>
>
>
> Please visit the Children and AIDS community homepage to view discussion
> archives, library, and more! http://knowledge-gateway.org/childrenandaids
>
> You are receiving this message because you are a member of the community Children
> and AIDS <https://knowledge-gateway.org/childrenandaids>.
>
> View this contribution on the web site
> <https://knowledge-gateway.org/_/m585jzh7>
>
> A reply to this message will be sent to all members of Children and AIDS.
>
> Reply to sender <jerodrigues@unicef.org> | Unsubscribe
> <leave.childrenandaids@knowledge-gateway.org>
>


--

*Pierre Claver BONI A.*

Assistant Site/Bouaké SUD

*+*225 79559133 (Mobile)*|**perrieclevar@yahoo.fr*
<%7Cperrieclevar@yahoo.fr>

+225 79490953 (Office)*|cboni@ccp.ci <%7Ccboni@ccp.ci>*

Skype: clevar 7

*www.breakthroughactionandresearch.org
<http://www.breakthroughactionandresearch.org/>*

*https://www.facebook.com/JHUCCP.Cotedivoire/
<https://www.facebook.com/JHUCCP.Cotedivoire/>*